Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease, Infectious Disease, Hospital
Therapuetic Areas:Immunology / Infectious Diseases, Nephrology / Urology, Other
Healthy:No
Age Range:18 - Any
Updated:9/14/2018
Start Date:March 13, 2017
End Date:October 21, 2019
Contact:Christina Rose, Pharm.D.
Email:rosecm@temple.edu
Phone:215-707-8057

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration

The study's primary objective is to determine plasma and dialysis fluid concentrations in
patients prescribed ceftazidime-avibactam as the standard treatment for their infection and
requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment
for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics
of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the
prescribed dose meets pharmacodynamic targets.


Inclusion Criteria:

- Adults > 18 years of age

- Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic
renal failure

- documented or suspected infection requiring a prescription for ceftazidime-avibactam

Exclusion Criteria:

- Patients on CRRT < 24 hours

- Patients on ceftazidime-avibactam < 24 hours

- Patients unable to remain on CRRT for 32 hours continuously without clotting
We found this trial at
1
site
Temple University Hospital
3401 N Broad St
Philadelphia, Pennsylvania
(215) 707-2000
Phone: 215-707-8057
Temple University Hospital On January 18, 1892 a three-story house at 3403 North Broad Street...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials